New perspectives in glutamate and anxiety

Pharmacology Biochemistry and Behavior

Volumn 100, Issue 4, 2012, Pages 752-774

  Riaza Bermudo Soriano, Carlos ^a   Perez Rodriguez, M Mercedes ^b   Vaquero Lorenzo, Concepcion ^c,d   Baca Garcia, Enrique ^c,e,f  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^e HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^f NewYork Presbyterian Hospital   (United States)

Author keywords

Anxiety; Fear conditioning; Glutamate; Polyamines

Indexed keywords

1 AMINO 1,5 INDANDICARBOXYLIC ACID; 2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 AMINO 3 (3,4 DICHLOROBENZYLOXY) 6 FLUOROBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; 2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; 2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID ETHYL ESTER; 2 AMINO 4,5 (1,2 CYCLOHEXYL) 7 PHOSPHONOHEPTANOIC ACID; 2 AMINO 5 PHOSPHONOVALERIC ACID; 2 AMINO 7 PHOSPHONOHEPTANOIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; 7 CHLORO 4 HYDROXY 3 (3 PHENOXYPHENYL) 2 QUINOLONE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; CHLORPHENIRAMINE MALEATE PLUS PHENYLEPHRINE; CORTICOTROPIN RELEASING FACTOR; CYCLOSERINE; DIZOCILPINE; DOPAMINE; EGLUMETAD; FENOBAM; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR AGONIST; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; KAINIC ACID RECEPTOR; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 5; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RILUZOLE; SEROTONIN; TALAGLUMETAD; TEZAMPANEL; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANXIETY DISORDER; BASAL AMYGDALA; CENTRAL NUCLEUS (AMYGDALA); DRUG WITHDRAWAL; GENE EXPRESSION; HIPPOCAMPUS; HUNTINGTON CHOREA; HYDROCORTISONE RELEASE; HYPERTENSION; HYPERTHERMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LATERAL AMYGDALA; LEARNING; MACROMOLECULE; MEMBRANE DEPOLARIZATION; MEMORY; MOOD DISORDER; NERVE CELL DIFFERENTIATION; NEUROTRANSMISSION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; STRESS; TACHYCARDIA;

ANIMALS; ANXIETY; GLUTAMIC ACID; HUMANS; POLYAMINES; STRESS, PSYCHOLOGICAL;

ANIMALIA;

EID: 84855557353     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2011.04.010     Document Type: Review

References (375)

1. Aboujaoude E, Barry JJ, Gamel N. Memantine augmentation in treatment-resistant obsessive - compulsive disorder: an open-label trial. J Clin Psychopharmacol 2009;29:51-5.
2. Aizenman CD, Munoz-Elias G, Cline HT. Visually driven modulation of glutamatergic synaptic transmission is mediated by the regulation of intracellular polyamines. Neuron 2002;34:623-34. (Pubitemid 34628758)
3. Alonso J, Lepine JP. Overview of key data from the European Study of the Epidemiology of Mental Disorders (ESEMeD). J Clin Psychiatry 2007;68(Suppl. 2):3-9. (Pubitemid 46333560)
4. American Psychiatric Association. American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium 2006; 2006.
5. Amorapanth P, Ledoux JE, Nader K. Different lateral amygdala outputs mediate reactions and actions elicited by a fear-arousing stimulus. Nat Neurosci 2000;3:74-9. (Pubitemid 30126351)
6. Andrews RC. The side effects of antimalarial drugs indicates a polyamine involvement in both schizophrenia and depression. Med Hypotheses 1985;18:11-8. (Pubitemid 15020317)
7. Anthony EW, Nevins ME. Anxiolytic-like effects of N-methyl-D-aspartate- associated glycine receptor ligands in the rat potentiated startle test. Eur J Pharmacol 1993;250(2):317-24. (Pubitemid 23357382)
8. Aricioglu F, Altunbas H. Is agmatine an endogenous anxiolytic/ antidepressant agent? Ann NY Acad Sci 2003;1009:136-40. (Pubitemid 38265098)
9. Arnold PD, Rosenberg DR, Mundo E, Tharmalingam S, Kennedy JL, Richter MA. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive - compulsive disorder: a preliminary study. Psychopharmacology (Berl) 2004;174:530-8. (Pubitemid 39119342)
10. Aupperle RL, Hale LR, Chambers RJ, Cain SE, Barth FX, Sharp SC, et al. An fMRI study examining effects of acute D-cycloserine during symptom provocation in spider phobia. CNS Spectr 2009;14:556-71.
11. Ballard TM, Woolley ML, Prinssen E, Huwyler J, Porter R, Spooren W. The effect of the mGlu5 receptor antagonist MPEP in rodent tests of anxiety and cognition: a comparison. Psychopharmacology (Berl) 2005;179:218-29. (Pubitemid 40576709)
12. Banasr M, Chowdhury GM, Terwilliger R, Newton SS, Duman RS, Behar KL, et al. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry 2010;15:501-11.
13. Barkus C, McHugh SB, Sprengel R, Seeburg PH, Rawlins JN, Bannerman DM. Hippocampal NMDA receptors and anxiety: at the interface between cognition and emotion. Eur J Pharmacol 2010;626:49-56.
14. Barros DM, Izquierdo LA, Mello e Souza, Ardenghi PG, Pereira P, Medina JH, et al. Molecular signalling pathways in the cerebral cortex are required for retrieval of one-trial avoidance learning in rats. Behav Brain Res 2000;114:183-92.
15. Bartha R, Drost DJ, Menon RS, Williamson PC. Comparison of the quantification precision of human short echo time (1)H spectroscopy at 1.5 and 4.0 Tesla 35. Magn Reson Med 2000;44:185-92. (Pubitemid 30614776)
16. Bastida CM, Cremades A, Castells MT, López-Contreras AJ, López-García C, Sánchez-Mas J, et al. Sexual dimorphism of ornithine decarboxylase in the mouse adrenal: influence of polyamine deprivation on catecholamine and corticoid level. Am J Physiol Endocrinol Metab 2007:1010-7.
17. Battista MA, Hierholzer R, Khouzam HR, Barlow A, O'Toole S. Pilot trial of memantine in the treatment of posttraumatic stress disorder. Psychiatry 2007;70:167-74. (Pubitemid 47195721)
18. Bauer EP, Schafe GE, Le Doux JE. Different induction protocols recruit NMDA and L-type calcium channel-dependent LTP in the lateral amygdala: correlation with fear memory. Soc Neurosci 2000:1253.
19. Bauer EP, Schafe GE, Ledoux JE. NMDA receptors and L-type voltage-gated calcium channels contribute to long-term potentiation and different components of fear memory formation in the lateral amygdala. J Neurosci 2002;22:5239-49. (Pubitemid 37465637)
20. Becker A, Peters B, Schroeder H, Mann T, Huether G, Grecksch G. Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:687-700. (Pubitemid 36645072)
21. Becquet D, Hery M, Francois-Bellan AM, Giraud P, Deprez P, Faudon M, et al. Glutamate, GABA, glycine and taurine modulate serotonin synthesis and release in rostral and caudal rhombencephalic raphe cells in primary cultures. Neurochem Int 1993;23:269-83.
22. Benvenga MJ, overshinner CD, Monn JA, Leander JD. Disinhibitory effects of LY354470, a new mgluR2 agonist, on behavior suppressed by electric shock in rats and pigeons. Drug Dev Res 1999;47:37-44. (Pubitemid 29293571)
23. Bergink V, Westenberg HG. Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740. Int Clin Psychopharmacol 2005;20:291-3. (Pubitemid 41475316)
24. Bergink V, van Megen HJ, Westenberg HG. Glutamate and anxiety. Eur Neuropsychopharmacol 2004;14:175-83. (Pubitemid 38410952)
25. Berlant JL. Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder. BMC Psychiatry 2004;4:24.
26. Berlant J, van Kammen DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry 2002;63:15-20. (Pubitemid 34113481)
27. Berlese DB, Sauzem PD, Carati MC, Guerra GP, Stiegemeier JA, Mello CF, et al. Time-dependent modulation of inhibitory avoidance memory by spermidine in rats. Neurobiol Learn Mem 2005;83:48-53. (Pubitemid 40018026)
28. Berlin HA. Antiepileptic drugs for the treatment of post-traumatic stress disorder. Curr Psychiatry Rep 2007;9:291-300. (Pubitemid 47490000)
29. Bertoglio LJ, Carobrez AP. Anxiolytic-like effects of NMDA/glycine-B receptor ligands are abolished during the elevated plus-maze trial 2 in rats. Psychopharmacology (Berl) 2003;170:335-42. (Pubitemid 38010504)
30. Bhattacharyya S, Khanna S, Chakrabarty K, Mahadevan A, Christopher R, Shankar SK. Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive - compulsive disorder. Neuropsychopharmacology 2009;34:2489-96.
31. Bhattacharyya SK, Sen AP, Upadhyay SN. Anxiolytic activity of piracetam, a nootropic agent, following subchronic administration in rodents. Indian J Exp Biol 1993;31:902-7. (Pubitemid 24090856)
32. Blair HT, Schafe GE, Bauer EP, Rodrigues SM, Ledoux JE. Synaptic plasticity in the lateral amygdala: a cellular hypothesis of fear conditioning. Learn Mem 2001;8:229-42. (Pubitemid 32959636)
33. Blair HT, Sotres-Bayon F, Moita MA, Ledoux JE. The lateral amygdala processes the value of conditioned and unconditioned aversive stimuli. Neuroscience 2005;133:561-9. (Pubitemid 40726222)
34. Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993;361:31-9. (Pubitemid 23020772)
35. Bliss TV, Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol 1973:331-56.
36. Bourtchouladze R, Abel T, Berman N, Gordon R, Lapidus K, Kandel ER. Different training procedures recruit either one or two critical periods for contextual memory consolidation, each of which requires protein synthesis and PKA. Learn Mem 1998;5:365-74. (Pubitemid 29115266)
37. Brann DW, Mahesh VB. Excitatory amino acids: evidence for a role in the control of reproduction and anterior pituitary hormone secretion. Endocr Rev 1997;18:678-700. (Pubitemid 27435540)
38. Bremner JD, Mletzko T, Welter S, Quinn S, Williams C, Brummer M, et al. Effects of phenytoin on memory, cognition and brain structure in post-traumatic stress disorder: a pilot study. J Psychopharmacol 2005;19:159-65. (Pubitemid 40577220)
39. Britton JC, Gold AL, Feczko EJ, Rauch SL, Williams D, Wright CI. D-cycloserine inhibits amygdala responses during repeated presentations of faces. CNS Spectr 2007;12:600-5. (Pubitemid 47329496)
40. Brodkin J, Bradbury M, Busse C, Warren N, Bristow LJ, Varney MA. Reduced stress-induced hyperthermia in mGluR5 knockout mice. Eur J Neurosci 2002a;16(11):2241-4. (Pubitemid 35454269)
41. Brodkin J, Busse C, Sukoff SJ, Varney MA. Anxiolytic-like activity of the mGluR5 antagonist MPEP: a comparison with diazepam and buspirone. Pharmacol Biochem Behav 2002b;73(2):359-66. (Pubitemid 34773437)
42. Bueno AB, Collado I, de DA, Dominguez C, Martin JA, Martin LM, et al. Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist. J Med Chem 2005;48(16):5305-20. (Pubitemid 41113916)
43. Busse CS, Brodkin J, Tattersall D, Anderson JJ, Warren N, Tehrani L, et al. The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology 2004;29:1971-9. (Pubitemid 39486548)
44. Buttelmann B, Peters JU, Ceccarelli S, Kolczewski S, Vieira E, Prinssen EP, et al. Arylmethoxypyridines as novel, potent and orally active mGlu5 receptor antagonists. Bioorg Med Chem Lett 2006;16(7):1892-7. (Pubitemid 43267372)
45. Camera K, Mello CF, Ceretta AP, Rubin MA. Systemic administration of polyaminergic agents modulate fear conditioning in rats. Psychopharmacology (Berl) 2007;192:457-64. (Pubitemid 46870741)
46. Campeau S, Miserendino MJ, Davis M. Intra-amygdala infusion of the N-methyl-D-aspartate receptor antagonist AP5 blocks acquisition but not expression of fear-potentiated startle to an auditory conditioned stimulus. Behav Neurosci 1992;106:569-74.
47. Chaki S, Yoshikawa R, Hirota S, Shimazaki T, Maeda M, Kawashima N, et al. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology 2004;46(4):457-67. (Pubitemid 38224431)
48. Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology 2005;30:1735-40. (Pubitemid 43086030)
49. Chambers RA, Bremner JD, Moghaddam B, Southwick SM, Charney DS, Krystal JH. Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation. Semin Clin Neuropsychiatry 1999;4:274-81.
50. Chapman PF, Kairiss EW, Keenan CL, Brown TH. Long-term synaptic potentiation in the amygdala. Synapse 1990;6:271-8. (Pubitemid 20354432)
51. Charney DS, Deutch A. A functional neuroanatomy of anxiety and fear: implications for the pathophysiology and treatment of anxiety disorders. Crit Rev Neurobiol 1996;10:419-46. (Pubitemid 27036106)
52. Chen GG, Fiori LM, Moquin L, Gratton A, Mamer O, Mechawar N, et al. Evidence of altered polyamine concentrations in cerebral cortex of suicide completers. Neuropsychopharmacology 2010;35:1477-84.
53. Cheramy A, Romo R, Godeheu G, Baruch P, Glowinski J. In vivo presynaptic control of dopamine release in the cat caudate nucleus-II. Facilitatory or inhibitory influence of L-glutamate. Neuroscience 1986;19:1081-90. (Pubitemid 17217005)
54. Chojnacka-Wojcik E, Tatarczynska E, ren-Wesolek A. Effect of glycine on antidepressant-and anxiolytic-like action of 1-aminocyclopropanecarboxylic acid (ACPC) in rats. Pol J Pharmacol 1996;48(6):627-9.
55. Chojnacka-Wojcik E, Tatarczynska E, Pilc A. The anxiolytic-like effect of metabotropic glutamate receptor antagonists after intrahippocampal injection in rats. Eur J Pharmacol 1997;319(2-3):153-6. (Pubitemid 27056033)
56. Collins DR, Pare D. Differential fear conditioning induces reciprocal changes in the sensory responses of lateral amygdala neurons to the CS(+) and CS(-). Learn Mem 2000;7:97-103. (Pubitemid 30213023)
57. Connor KM, Davidson JR, Weisler RH, Zhang W, Abraham K. Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology (Berl) 2006;184:21-5. (Pubitemid 43005753)
58. Conrad CD, Ledoux JE, Magarinos AM, McEwen BS. Repeated restraint stress facilitates fear conditioning independently of causing hippocampal CA3 dendritic atrophy. Behav Neurosci 1999;113:902-13. (Pubitemid 30130866)
59. Coplan JD, Mathrew SJ, Smith EL, Trost RC, Scharf BA, Martinez J. Effects of LY354740, a novel glutamatergic metabotropic agonist, on nonhuman primate hypothalamicpituitary-adrenal axis and noradrenergic function. CNS Spectr 2001;6:606-12.
60. Corbett R, Dunn RW. Effects of HA-966 on conflict, social interaction and plus maze behaviour. Drug Dev Res 1991;24:201.
61. Corbett R, Dunn RW. Effects of 5,7 dichlorokynurenic acid on conflict, social interaction and plus maze behaviors. Neuropharmacology 1993;32:461-6. (Pubitemid 23161555)
62. Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, et al. Riluzole augmentation in treatment-resistant obsessive - compulsive disorder: an openlabel trial. Biol Psychiatry 2005;58:424-8. (Pubitemid 41219711)
63. Cortese BM, Phan KL. The role of glutamate in anxiety and related disorders. CNS Spectr 2005;10:820-30. (Pubitemid 41531936)
64. Cortese BM, Mitchell TR, Galloway MP, Prevost KE, Fang J, Moore GJ, et al. Region-specific alteration in brain glutamate: possible relationship to risk-taking behavior. Physiol Behav 2010;99:445-50.
65. Cosford ND, Tehrani L, Roppe J, Schweiger E, Smith ND, Anderson J, et al. 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J Med Chem 2003;46:204-6. (Pubitemid 36078139)
66. Cratty MS, Birkle DL. N-methyl-D-aspartate (NMDA)-mediated corticotropin-releasing factor (CRF) release in cultured rat amygdala neurons1810. Peptides 1999;20:93-100. (Pubitemid 29158800)
67. Czlonkowska A, Siemiatkowski M, Plaznik A. Some behavioral effects of AMPA/kainate receptor agonist and antagonists. J Physiol Pharmacol 1997;48(3):479-88. (Pubitemid 27421491)
68. da Silva WC, Bonini JS, Bevilaqua LR, Izquierdo I, Cammarota M. Histamine enhances inhibitory avoidance memory consolidation through a H2 receptor-dependent mechanism. Neurobiol Learn Mem 2006;86:100-6. (Pubitemid 43776642)
69. Dahel KA, Al-Saffar NM, Flayeh KA. Polyamine oxidase activity in sera of depressed and schizophrenic patients after ECT treatment. Neurochem Res 2001;26:415-8. (Pubitemid 32685961)
70. Das I, de Belleroche J, Essali MA, Richardson-Andrews RC, Hirsch SR. Blood polyamine in schizophrenia. Schizophr Res 1989;2:146.
71. Das I, Ramchand CN, Gliddon A, Hirsch SR. Nitric oxide, free radicals and polyamines may have a role in the membrane pathology of schizophrenia. Neuropsychobiology 1998;37:65-7.
72. Davidson RJ. Anxiety and affective style: role of prefrontal cortex and amygdala. Biol Psychiatry 2002;51:68-80. (Pubitemid 34093795)
73. Davidson JR, Brady K, Mellman TA, Stein MB, Pollack MH. The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol 2007;27:85-8. (Pubitemid 46105772)
74. Davis RH, Morris DR, Coffino P. Sequestered end products and enzyme regulation: the case of ornithine decarboxylase. Microbiol Rev 1992;56:280-90.
75. Davis M, Ressler K, Rothbaum BO, Richardson R. Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry 2006;60:369-75. (Pubitemid 44215855)
76. Day DE, Cooper MA, Markham CM, Huhman KL. NR2B subunit of the NMDA receptor in the basolateral amygdala is necessary for the acquisition of conditioned defeat in Syrian hamsters. Behav Brain Res 2010.
77. Douglas BJ, Mletzko T, Welter S, Siddiq S, Reed L, Williams C, et al. Treatment of posttraumatic stress disorder with phenytoin: an open-label pilot study. J Clin Psychiatry 2004;65:1559-64.
78. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997;54:597-606. (Pubitemid 27306570)
79. Dunayevich E, Erickson J, Levine L, Landbloom R, Schoepp DD, Tollefson GD. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 2008;33:1603-10. (Pubitemid 351684700)
80. Dunn RW, Corbett R, Fielding S. Effects of 5-HT1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze. Eur J Pharmacol 1989;169:1-10. (Pubitemid 19244943)
81. Ekegren, T. Transmethylation, Polyamines and Apoptosis in Amyothrophic Lateral Sclerosis. 2005. Uppsala University. 2004.Ref Type: Thesis/Dissertation.
82. Elvander-Tottie E, Eriksson TM, Sandin J, Ogren SO. N-methyl-D-aspartate receptors in the medial septal area have a role in spatial and emotional learning in the rat. Neuroscience 2006;142:963-78. (Pubitemid 44636063)
83. Emmett MR, Mick SJ, Cler JA, Rao TS, Iyengar S, Wood PL. Actions of D-cycloserine at the N-methyl-D-aspartate-associated glycine receptor site in vivo. Neuropharmacology 1991;30:1167-71.
84. Ernst C, Mechawar N, Turecki G. Suicide neurobiology. Prog Neurobiol 2009;89:315-33.
85. Fanselow MS, Kim JJ, Yipp J, De OB. Differential effects of the N-methyl-D-aspartate antagonist DL-2-amino-5-phosphonovalerate on acquisition of fear of auditory and contextual cues. Behav Neurosci 1994;108:235-40. (Pubitemid 24142685)
86. Fendt M. Expression and conditioned inhibition of fear-potentiated startle after stimulation and blockade of AMPA/Kainate and GABA(A) receptors in the dorsal periaqueductal gray. Brain Res 2000;880(1-2):1-10.
87. Fendt M. Injections of the NMDA receptor antagonist aminophosphonopentanoic acid into the lateral nucleus of the amygdala block the expression of fear-potentiated startle and freezing. J Neurosci 2001;21:4111-5. (Pubitemid 32466503)
88. Fendt M, Koch M, Schnitzler HU. NMDA receptors in the pontine brainstem are necessary for fear potentiation of the startle response. Eur J Pharmacol 1996;318:1-6. (Pubitemid 27033195)
89. Fendt M, Schmid S, Thakker DR, Jacobson LH, Yamamoto R, Mitsukawa K, et al. mGluR7 facilitates extinction of aversive memories and controls amygdala plasticity. Mol Psychiatry 2008;13:970-9.
90. Feusner JD, Kerwin L, Saxena S, Bystritsky A. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacol Bull 2009;42:81-93.
91. Fiori LM, Turecki G. Implication of the polyamine system in mental disorders. J Psychiatry Neurosci 2008;33:102-10. (Pubitemid 351441380)
92. Flint AC, Maisch US, Weishaupt JH, Kriegstein AR, Monyer H. NR2A subunit expression shortens NMDA receptor synaptic currents in developing neocortex. J Neurosci 1997;17:2469-76. (Pubitemid 27137413)
93. Fraser CM, Cooke MJ, Fisher A, Thompson ID, Stone TW. Interactions between ifenprodil and dizocilpine on mouse behaviour in models of anxiety and working memory. Eur Neuropsychopharmacol 1996;6:311-6. (Pubitemid 26422792)
94. Frerking M, Nicoll RA. Synaptic kainate receptors. Curr Opin Neurobiol 2000;10:342-51. (Pubitemid 30389301)
95. Galici R, Echemendia NG, Rodriguez AL, Conn PJ. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther 2005;315(3):1181-7. (Pubitemid 41635406)
96. Garakani A, Mathew SJ, Charney DS. Neurobiology of anxiety disorders and implications for treatment. Mt Sinai J Med 2006;73:941-9. (Pubitemid 46040391)
97. Gasparini F, Spooren W. Allosteric modulators for mGlu receptors. Curr Neuropharmacol 2007;5:187-94. (Pubitemid 351863860)
98. Gilad GM, Gilad VH. Overview of the brain polyamine-stress-response: regulation, development, and modulation by lithium and role in cell survival. Cell Mol Neurobiol 2003;23:637-49. (Pubitemid 37071490)
99. Giouzeli M, Williams NA, Lonie LJ, DeLisi LE, Crow TJ. ProtocadherinX/Y, a candidate gene-pair for schizophrenia and schizoaffective disorder: a DHPLC investigation of genomic sequence. Am J Med Genet B Neuropsychiatr Genet 2004;129B:1-9. (Pubitemid 38989056)
100. Gomes GM, Mello CF, da Rosa MM, Bochi GV, Ferreira J, Barron S, et al. Polyaminergic agents modulate contextual fear extinction in rats. Neurobiol Learn Mem 2010;93:589-95.
101. Gomperts SN, Rao A, Craig AM, Malenka RC, Nicoll RA. Postsynaptically silent synapses in single neuron cultures. Neuron 1998;21:1443-51. (Pubitemid 29022545)
102. Gong ZH, Li YF, Zhao N, Yang HJ, Su RB, Luo ZP, et al. Anxiolytic effect of agmatine in rats and mice. Eur J Pharmacol 2006;550:112-6. (Pubitemid 44572272)
103. Goosens KA, Maren S. Contextual and auditory fear conditioning are mediated by the lateral, basal, and central amygdaloid nuclei in rats. Learn Mem 2001;8:148-55. (Pubitemid 32552863)
104. Grant P, Lougee L, Hirschtritt M, Swedo SE. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive - compulsive disorder. J Child Adolesc Psychopharmacol 2007;17:761-7. (Pubitemid 351158597)
105. Grillon C, Cordova J, Levine LR, Morgan III CA. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology (Berl) 2003;168:446-54. (Pubitemid 36994028)
106. Guastella AJ, Lovibond PF, Dadds MR, Mitchell P, Richardson R. A randomized controlled trial of the effect of D-cycloserine on extinction and fear conditioning in humans. Behav Res Ther 2007;45:663-72. (Pubitemid 46282625)
107. Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry 2008;63:544-9.
108. Guerra GP, Mello CF, Sauzem PD, Berlese DB, Furian AF, Tabarelli Z, et al. Nitric oxide is involved in the memory facilitation induced by spermidine in rats. Psychopharmacology (Berl) 2006;186:150-8. (Pubitemid 43727331)
109. Guimaraes FS, Carobrez AP, De Aguiar JC, Graeff FG. Anxiolytic effect in the elevated plus-maze of the NMDA receptor antagonist AP7 microinjected into the dorsal periaqueductal grey. Psychopharmacology (Berl) 1991;103:91-4.
110. Guipponi M, Deutsch S, Kohler K, Perroud N, Le GF, Vessaz M, et al. Genetic and epigenetic analysis of SSAT gene dysregulation in suicidal behavior. Am J Med Genet B Neuropsychiatr Genet 2008.
111. Hageman I, Andersen HS, Jorgensen MB. Post-traumatic stress disorder: a review of psychobiology and pharmacotherapy. Acta Psychiatr Scand 2001;104:411-22. (Pubitemid 33151428)
112. Halaris A, Zhu H, Feng Y, Piletz JE. Plasma agmatine and platelet imidazoline receptors in depression. Ann NY Acad Sci 1999;881:445-51. (Pubitemid 29349539)
113. Halonen T, Sivenius J, Miettinen R, Halmekyto M, Kauppinen R, Sinervirta R, et al. Elevated seizure threshold and impaired spatial learning in transgenic mice with putrescine overproduction in the brain. Eur J Neurosci 1993;5:1233-9. (Pubitemid 23258944)
114. Hammer MB, Robert S, Frueh BC. Treatment-resistant prosttraumatic stress disorder: strategies for intervention. CNS Spectr 2004;9:740-52 (Ref Type: Abstract).
115. Hayase T, Yamamoto Y, Yamamoto K. Behavioral effects of ketamine and toxic interactions with psychostimulants. BMC Neurosci 2006;7:25.
116. Helton DR, Tizzano JP,Monn JA, SchoeppDD, KallmanMJ. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther 1998;284:651-60. (Pubitemid 28086655)
117. Heresco-Levy U, Kremer I, Javitt DC, Goichman R, Reshef A, Blanaru M, et al. Pilotcontrolled trial of D-cycloserine for the treatment of post-traumatic stress disorder. Int J Neuropsychopharmacol 2002;5:301-7. (Pubitemid 35470350)
118. Heresco-Levy U, Vass A, Bloch B, Wolosker H, Dumin E, Balan L, et al. Pilot controlled trial of D-serine for the treatment of post-traumatic stress disorder. Int J Neuropsychopharmacol 2009;12:1275-82.
119. Herman JP, Eyigor O, Ziegler DR, Jennes L. Expression of ionotropic glutamate receptor subunit mRNAs in the hypothalamic paraventricular nucleus of the rat. J Comp Neurol 2000;422:352-62. (Pubitemid 30387667)
120. Herry C, Ciocchi S, Senn V, Demmou L, Muller C, Luthi A. Switching on and off fear by distinct neuronal circuits. Nature 2008;454:600-6.
121. Hertzberg MA, Butterfield MI, Feldman ME, Beckham JC, Sutherland SM, Connor KM, et al. A preliminary study of lamotrigine for the treatment of post traumatic stress disorder. Biol Psychiatry 1999;45:1226-9. (Pubitemid 29236566)
122. Hestrin S. Activation and desensitization of glutamate-activated channels mediating fast excitatory synaptic currents in the visual cortex. Neuron 1992a;9:991-9.
123. Hestrin S. Developmental regulation of NMDA receptor-mediated synaptic currents at a central synapse. Nature 1992b;357:686-9.
124. Hicks TP, Conti F. Amino acids as the source of considerable excitation in cerebral cortex. Can J Physiol Pharmacol 1996;74:341-61. (Pubitemid 26261945)
125. Hirsch SR, Das I, Garey LJ, de Belleroche J. A pivotal role for glutamate in the pathogenesis of schizophrenia, and its cognitive dysfunction. Pharmacol Biochem Behav 1997;56:797-802. (Pubitemid 27189766)
126. Ho YJ, Hsu LS, Wang CF, Hsu WY, Lai TJ, Hsu CC, et al. Behavioral effects of d-cycloserine in rats: the role of anxiety level. Brain Res 2005;1043(1-2):179-85.
127. Hofmann SG, Pollack MH, Otto MW. Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine. CNS Drug Rev 2006;12:208-17. (Pubitemid 46047788)
128. Huang YY, Kandel ER. Postsynaptic induction and PKA-dependent expression of LTP in the lateral amygdala. Neuron 1998;21:169-78. (Pubitemid 28355701)
129. Huang YY, Martin KC, Kandel ER. Both protein kinase A and mitogen-activated protein kinase are required in the amygdala for the macromolecular synthesis-dependent late phase of long-term potentiation. J Neurosci 2000;20:6317-25.
130. Igarashi K, Kashiwagi K. Polyamines: mysterious modulators of cellular functions. Biochem Biophys Res Commun 2000;271:559-64. (Pubitemid 30444667)
131. Iijima M, Chaki S. Separation-induced ultrasonic vocalization in rat pups: further pharmacological characterization. Pharmacol Biochem Behav 2005 Dec;82(4):652-7. (Pubitemid 43184041)
132. Iijima M, Shimazaki T, Ito A, Chaki S. Effects of metabotropic glutamate 2/3 receptor antagonists in the stress-induced hyperthermia test in singly housed mice. Psychopharmacology (Berl) 2007;190:233-9. (Pubitemid 46011183)
133. Isaac JT, Nicoll RA, Malenka RC. Evidence for silent synapses: implications for the expression of LTP. Neuron 1995;15:427-34.
134. Isgor C, Kabbaj M, Akil H, Watson SJ. Delayed effects of chronic variable stress during peripubertal-juvenile period on hippocampal morphology and on cognitive and stress axis functions in rats. Hippocampus 2004;14:636-48. (Pubitemid 39107017)
135. Izquierdo I, Medina JH. Memory formation: the sequence of biochemical events in the hippocampus and its connection to activity in other brain structures. Neurobiol Learn Mem 1997;68:285-316. (Pubitemid 27506324)
136. Jaeschke G, Porter R, Buttelmann B, Ceccarelli SM, Guba W, Kuhn B, et al. Synthesis and biological evaluation of fenobam analogs as mGlu5 receptor antagonists. Bioorg Med Chem Lett 2007;17:1307-11. (Pubitemid 46240847)
137. Jardim MC, Guimaraes FS. GABAergic and glutamatergic modulation of exploratory behavior in the dorsomedial hypothalamus. Pharmacol Biochem Behav 2001;69(3-4):579-84. (Pubitemid 32758744)
138. Jardim MC, Guimaraes FS. Role of glutamate ionotropic receptors in the dorsomedial hypothalamic nucleus on anxiety and locomotor behavior. Pharmacol Biochem Behav 2004;79(3):541-6. (Pubitemid 39576172)
139. Jardim MC, Aguiar DC, Moreira FA, Guimaraes FS. Role of glutamate ionotropic and benzodiazepine receptors in the ventromedial hypothalamic nucleus on anxiety. Pharmacol Biochem Behav 2005;82:182-9. (Pubitemid 41423502)
140. Jasnow AM, Cooper MA, Huhman KL. N-methyl-D-aspartate receptors in the amygdala are necessary for the acquisition and expression of conditioned defeat. Neuroscience 2004;123:625-34. (Pubitemid 38045401)
141. Jedema HP, Moghddam B. Characterization of excitatory amino acid modulation of dopamine release in the prefrontal cortex of conscious rats. J Neurochem 1996;66:1448-53. (Pubitemid 26090547)
142. Jessa M, Nazar M, Plaznik A. Anxiolytic-like action of intra-hippocampally administered NMDA antagonists in rats. Pol J Pharmacol 1995;47:81-4.
143. Jessa M, Nazar M, Bidzinski A, Plaznik A. The effects of repeated administration of diazepam, MK-801 and CGP 37849 on rat behavior in two models of anxiety. Eur Neuropsychopharmacol 1996;6:55-61. (Pubitemid 26100034)
144. Joanny P, Steinberg J, Oliver C, Grino M. Glutamate and N-methyl-D-aspartate stimulate rat hypothalamic corticotropin-releasing factor secretion in vitro. J Neuroendocrinol 1997;9:93-7. (Pubitemid 27060114)
145. Johnson MP, Barda D, Britton TC, Emkey R, Hornback WJ, Jagdmann GE, et al. Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology (Berl) 2005;179(1):271-83. (Pubitemid 40576715)
146. Johnston D, Hoffman DA, Colbert CM, Magee JC. Regulation of back-propagating action potentials in hippocampal neurons1. Curr Opin Neurobiol 1999;9:288-92. (Pubitemid 29267598)
147. Julio-Pieper M, Hyland NP, Bravo JA, Dinan TG, Cryan JF. A novel role for the metabotropic glutamate receptor-7: modulation of faecal water content and colonic electrolyte transport in the mouse. Br J Pharmacol 2010;160:367-75.
148. Kaasinen SK, Oksman M, Alhonen L, Tanila H, Janne J. Spermidine/spermine N1-acetyltransferase overexpression in mice induces hypoactivity and spatial learning impairment. Pharmacol Biochem Behav 2004;78:35-45. (Pubitemid 38670511)
149. Kaiser LG, Schuff N, Cashdollar N, Weiner MW. Age-related glutamate and glutamine concentration changes in normal human brain: 1H MR spectroscopy study at 4 T. Neurobiol Aging 2005;26:665-72. (Pubitemid 40228758)
150. Kaplan GB, Moore KA. The use of cognitive enhancers in animal models of fear extinction. Pharmacol Biochem Behav 2011.
151. Kapus GL, Gacsalyi I, Vegh M, Kompagne H, Hegedus E, Leveleki C, et al. Antagonism of AMPA receptors produces anxiolytic-like behavior in rodents: effects of GYKI 52466 and its novel analogues. Psychopharmacology (Berl) 2008;198:231-41.
152. Karcz-Kubicha M, JessaM, Nazar M, Plaznik A, Hartmann S, Parsons CG, et al. Anxiolytic activity of glycine-B antagonists and partial agonists - no relation to intrinsic activity in the patch clamp. Neuropharmacology 1997;36:1355-67. (Pubitemid 27502193)
153. Ke Y, Cohen BM, Bang JY, Yang M, Renshaw PF. Assessment of GABA concentration in human brain using two-dimensional proton magnetic resonance spectroscopy. Psychiatry Res 2000;100:169-78.
154. Kellner M, Muhtz C, Stark K, Yassouridis A, Arlt J, Wiedemann K. Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results. Psychopharmacology (Berl) 2005;179:310-5. (Pubitemid 40576719)
155. Kew JN, Kemp JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl) 2005;179:4-29. (Pubitemid 40576690)
156. Khan S, Liberzon I. Topiramate attenuates exaggerated acoustic startle in an animal model of PTSD. Psychopharmacology (Berl) 2004;172(2):225-9. (Pubitemid 38388773)
157. Kilpeläinen, P. Ornithine Decarboxylase. Expression and regulation in rat brain and in transgenic mice.11750. 25-3-2002. Department of Biochemistry, University of Oulu. Ref Type: Thesis/Dissertation.
158. Kita I, Seki Y, Nakatani Y, Fumoto M, Oguri M, Sato-Suzuki I, et al. Corticotropin-releasing factor neurons in the hypothalamic paraventricular nucleus are involved in arousal/yawning response of rats. Behav Brain Res 2006;169:48-56. (Pubitemid 43277470)
159. Klempan TA, Rujescu D, Merette C, Himmelman C, Sequeira A, Canetti L, et al. Profiling brain expression of the spermidine/spermine N1-acetyltransferase 1 (SAT1) gene in suicide. Am J Med Genet B Neuropsychiatr Genet 2009;150B:934-43.
160. Klodzinska A, Chojnacka-Wojcik E. Anticonflict effect of the glycineB receptor partial agonist, D-cycloserine, in rats. Pharmacological analysis. Psychopharmacology (Berl) 2000;152(2):224-8.
161. Klodzinska A, Chojnacka-Wojcik E, Palucha A, Branski P, Popik P, Pilc A. Potential antianxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology 1999;38(12):1831-9. (Pubitemid 29509721)
162. Klodzinska A, Tatarczynska E, Chojnacka-Wojcik E, Pilc A. Anxiolytic-like effects of group I metabotropic glutamate antagonist 2-methyl-6-(phenylethynyl) -pyridine (MPEP) in rats. Pol J Pharmacol 2000;52(6):463-6. (Pubitemid 32045910)
163. Klodzinska A, Tatarczynska E, Stachowicz K, Chojnacka-Wojcik E. The anxiolytic-like activity of AIDA (1-aminoindan-1,5-dicarboxylic acid), an mGLu 1 receptor antagonist. J Physiol Pharmacol 2004;55:113-26. (Pubitemid 38524218)
164. Koch M. Microinjections of the metabotropic glutamate receptor agonist, trans-(+/-)-1-amino-cyclopentane-1,3-dicarboxylate (trans-ACPD) into the amygdala increase the acoustic startle response of rats. Brain Res 1993;629(1):176-9. (Pubitemid 23328805)
165. Konradi C, Heckers S. Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol Ther 2003;97:153-79. (Pubitemid 36138820)
166. Kotlinska J, Liljequist S. The putative AMPA receptor antagonist, LY326325, produces anxiolytic-like effects without altering locomotor activity in rats. Pharmacol Biochem Behav 1998;60:119-24. (Pubitemid 28236621)
167. Krystal JH. Neuroplasticity as a target for the pharmacotherapy of psychiatric disorders: new opportunities for synergy with psychotherapy. Biol Psychiatry 2007;62:833-4. (Pubitemid 47496150)
168. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Charney DS. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199-214. (Pubitemid 24081509)
169. Krystal JH, Mathew SJ, D'Souza DC, Garakani A, Gunduz-Bruce H, Charney DS. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs 2010;24:669-93.
170. Langton JM, Richardson R. The role of context in the re-extinction of learned fear. Neurobiol Learn Mem 2009;92:496-503.
171. Langton JM, Richardson R. The effect of D-cycloserine on immediate vs. delayed extinction of learned fear. Learn Mem 2010;17:547-51.
172. Lavinsky D, Arteni NS, Netto CA. Agmatine induces anxiolysis in the elevated plus maze task in adult rats. Behav Brain Res 2003;141:19-24. (Pubitemid 36382913)
173. Ledgerwood L, Richardson R, Cranney J. Effects of D-cycloserine on extinction of conditioned freezing. Behav Neurosci 2003;117(2):341-9. (Pubitemid 36384252)
174. Ledgerwood L, Richardson R, Cranney J. D-cycloserine and the facilitation of extinction of conditioned fear: consequences for reinstatement. Behav Neurosci 2004;118:505-13. (Pubitemid 38685318)
175. Ledoux JE. Emotion, memory and the brain. Sci Am 1994;270:50-7.
176. Ledoux J. The emotional brain, fear, and the amygdala. Cell Mol Neurobiol 2003;23:727-38.
177. Ledoux J. The amygdala. Curr Biol 2007;17:R868-74.
178. Ledoux JE, Farb CR. Neurons of the acoustic thalamus that project to the amygdala contain glutamate. Neurosci Lett 1991;134:145-9.
179. Lee H, Kim JJ. Amygdalar NMDA receptors are critical for new fear learning in previously fear-conditioned rats. J Neurosci 1998;18:8444-54. (Pubitemid 28465019)
180. Lee HJ, Choi JS, Brown TH, Kim JJ. Amygdalar NMDA receptors are critical for the expression of multiple conditioned fear responses. J Neurosci 2001;21:4116-24. (Pubitemid 32466504)
181. Lehmann H, Singh V, Ting P, Treit D, Parent M. Intra-amygdala infusions of the Nmethyl-D-aspartate receptor antagonist DL-2-amino-5-phosphopentanoic acid impair shock-probe avoidance, but not elevated plus-maze performance. Neurosci Abstr 2000;755:4 (Ref Type: Abstract).
182. Lehner M, Wislowska-Stanek A, Taracha E, Maciejak P, Szyndler J, Skorzewska A, et al. The effects of midazolam and d-cycloserine on the release of glutamate and GABA in the basolateral amygdala of low and high anxiety rats during extinction trial of a conditioned fear test. Neurobiol Learn Mem 2010;94(4):468-80.
183. Lepine JP. The epidemiology of anxiety disorders: prevalence and societal costs. J Clin Psychiatry 2002;63(Suppl. 14):4-8.
184. Lerma J. Kainate receptors keep the excitement high. Trends Neurosci 2001;24:139-40. (Pubitemid 32166817)
185. Lerma J, Paternain AV, Rodriguez-Moreno A, Lopez-Garcia JC. Molecular physiology of kainate receptors. Physiol Rev 2001;81:971-98. (Pubitemid 32611226)
186. Lev WB, Steward O. Synapses as associative memory elements in the hippocampal formation. Brain Res 1979:233-45. (Pubitemid 9229461)
187. Liao D, Hessler NA, Malinow R. Activation of postsynaptically silent synapses during pairing-induced LTP in CA1 region of hippocampal slice. Nature 1995;375:400-4.
188. Linden AM, Greene SJ, Bergeron M, Schoepp DD. Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions. Neuropsychopharmacology 2004;29(3):502-13. (Pubitemid 38365926)
189. Linden AM, Bergeron M, Schoepp DD. Comparison of c-Fos induction in the brain by the mGlu2/3 receptor antagonist LY341495 and agonist LY354740: evidence for widespread endogenous tone at brain mGlu2/3 receptors in vivo. Neuropharmacology 2005;49(Suppl 1):120-34. (Pubitemid 41115899)
190. Loftis JM, Janowsky A. The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol Ther 2003;97:55-85. (Pubitemid 35477804)
191. Luine V, Villegas M, Martinez C, McEwen BS. Repeated stress causes reversible impairments of spatial memory performance. Brain Res 1994;639:167-70. (Pubitemid 24067449)
192. Lynch GS, Dunwiddic T, Gribkoff V. Heterosynaptic depression: a postsynaptic correlate of long-term potentiation. Nature 1977:737-9. (Pubitemid 8073808)
193. Magee JC, Johnston D. A synaptically controlled, associative signal for Hebbian plasticity in hippocampal neurons. Science 1997;275:209-13. (Pubitemid 27034761)
194. Malenka RC. The role of postsynaptic calcium in the induction of long-term potentiation. Mol Neurobiol 1991;5:289-95.
195. Malenka RC, Nicoll RA. Long-term potentiation - a decade of progress? Science 1999;285:1870-4.
196. Maren S. Synaptic transmission and plasticity in the amygdala. An emerging physiology of fear conditioning circuits. Mol Neurobiol 1996;13:1-22. (Pubitemid 126733046)
197. Maren S, Aharonov G, Stote DL, Fanselow MS. N-methyl-D-aspartate receptors in the basolateral amygdala are required for both acquisition and expression of conditional fear in rats. Behav Neurosci 1996;110:1365-74. (Pubitemid 27009199)
198. Martin PD, Shapiro ML. Disparate effects of long-term potentiation on evoked potentials and single CA1 neurons in the hippocampus of anesthetized rats. Hippocampus 2000;10:207-12. (Pubitemid 30438656)
199. Marton LJ, Pegg AE. Polyamines as targets for therapeutic intervention. Annu Rev Pharmacol Toxicol 1995;35:55-91.
200. Matheus MG, Guimaraes FS. Antagonism of non-NMDA receptors in the dorsal periaqueductal grey induces anxiolytic effect in the elevated plus maze. Psychopharmacology (Berl) 1997;132:14-8. (Pubitemid 27303734)
201. Mathew SJ, Coplan JD, Schoepp DD, Smith EL, Rosenblum LA, Gorman JM. Glutamate-hypothalamic-pituitary-adrenal axis interactions: implications for mood and anxiety disorders. CNS Spectr 2001;6:555-64. (Pubitemid 32816522)
202. Mathew SJ, Shungu DC, Mao X, Smith EL, Perera GM, Kegeles LS, et al. A magnetic resonance spectroscopic imaging study of adult nonhuman primates exposed to early-life stressors. Biol Psychiatry 2003;54:727-35. (Pubitemid 37281389)
203. Mathew SJ, Amiel JM, Coplan JD, Fitterling HA, Sackeim HA, Gorman JM. Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry 2005;162:2379-81. (Pubitemid 41740219)
204. Mathew SJ, Price RB, Mao X, Smith EL, Coplan JD, Charney DS, et al. Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder. Biol Psychiatry 2008;63:891-8. (Pubitemid 351458451)
205. Mathiesen JM, Svendsen N, Brauner-Osborne H, Thomsen C, Ramirez MT. Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br J Pharmacol 2003;138:1026-30. (Pubitemid 36459824)
206. McCallum J, Kim JH, Richardson R. Impaired extinction retention in adolescent rats: effects of D-cycloserine. Neuropsychopharmacology 2010;35:2134-42.
207. McGurk JF, Bennett MV, Zukin RS. Polyamines potentiate responses of N-methyl-Daspartate receptors expressed in xenopus oocytes. Proc Natl Acad Sci U S A 1990;87:9971-4. (Pubitemid 120016566)
208. McKernan MG, Shinnick-Gallagher P. Fear conditioning induces a lasting potentiation of synaptic currents in vitro. Nature 1997;390:607-11. (Pubitemid 28016194)
209. McKinnon MC, Yucel K, Nazarov A, MacQueen GM. A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. J Psychiatry Neurosci 2009;34:41-54.
210. Menard J, Treit D. Intra-septal infusions of excitatory amino acid receptor antagonists have differential effects in two animal models of anxiety. Behav Pharmacol 2000;11:99-108. (Pubitemid 30315844)
211. Middleton FA, Mirnics K, Pierri JN, Lewis DA, Levitt P. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci 2002;22:2718-29. (Pubitemid 37465821)
212. Mikolajczak P, Okulicz-Kozaryn I, Kaminska E, Niedopad L, Polanska A, Gebka J. Effects of acamprosate and some polyamine site ligands of NMDA receptor on short-term memory in rats. Eur J Pharmacol 2002;444:83-96. (Pubitemid 34621337)
213. Millan MJ. N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review. Curr Drug Targets CNS Neurol Disord 2002;1:191-213.
214. Millan MJ. The neurobiology and control of anxious states. Prog Neurobiol 2003;70:83-244. (Pubitemid 37309295)
215. Millan MJ, Brocco M. The Vogel conflict test: procedural aspects, gamma-aminobutyric acid, glutamate and monoamines. Eur J Pharmacol 2003;463:67-96. (Pubitemid 36205073)
216. Mirza NR, Bright JL, Stanhope KJ, Wyatt A, Harrington NR. Lamotrigine has an anxiolyticlike profile in the rat conditioned emotional response test of anxiety: a potential role for sodium channels? Psychopharmacology (Berl) 2005;180(1):159-68. (Pubitemid 40897082)
217. Miserendino MJ, Sananes CB, Melia KR, Davis M. Blocking of acquisition but not expression of conditioned fear-potentiated startle by NMDA antagonists in the amygdala. Nature 1990;345:716-8.
218. Moghaddam B. Stress preferentially increases extraneuronal levels of excitatory amino acids in the prefrontal cortex: comparison to hippocampus and basal ganglia. J Neurochem 1993;60:1650-7. (Pubitemid 23127567)
219. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997;17:2921-7. (Pubitemid 27155025)
220. Moinard C, Cynober L, de Bandt JP. Polyamines: metabolism and implications in human diseases. Clin Nutr 2005;24:184-97. (Pubitemid 40392801)
221. Molchanov ML, Guimaraes FS. Anxiolytic-like effects of AP7 injected into the dorsolateral or ventrolateral columns of the periaqueductal gray of rats. Psychopharmacology (Berl) 2002;160:30-8. (Pubitemid 34169823)
222. Molina-Hernandez M, Tellez-Alcantara NP, Perez-Garcia J, Olivera-Lopez JI, Jaramillo MT. Antidepressant-like and anxiolytic-like actions of the mGlu5 receptor antagonist MTEP, microinjected into lateral septal nuclei of male Wistar rats. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(6):1129-35. (Pubitemid 43928236)
223. Monn JA, Valli MJ, Massey SM, Wright RA, Salhoff CR, Johnson BG, et al. Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3. 1.0] hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem 1997;40:528-37. (Pubitemid 27080033)
224. Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 1994;12:529-40. (Pubitemid 24100885)
225. Morgan DM. Polyamines. An overview. Mol Biotechnol 1999;11:229-50.
226. Morrison SE, Salzman CD. Re-valuing the amygdala. Curr Opin Neurobiol 2010;20:221-30.
227. Mueller HT, Meador-Woodruff JH. Expression of the NR3A subunit of the NMDA receptor in human fetal brain. Ann NY Acad Sci 2003;1003:448-51. (Pubitemid 38083095)
228. Mueller HT, Meador-Woodruff JH. NR3A NMDA receptor subunit mRNA expression in schizophrenia, depression and bipolar disorder. Schizophr Res 2004;71:361-70. (Pubitemid 39330514)
229. Myers KM, Carlezon Jr WA, Davis M. Glutamate receptors in extinction and extinction-based therapies for psychiatric illness. Neuropsychopharmacology 2011;36(1):274-93.
230. Nader K, Schafe GE, Le Doux JE. Fear memories require protein synthesis in the amygdala for reconsolidation after retrieval. Nature 2000;406:722-6.
231. Nader K, Majidishad P, Amorapanth P, Ledoux JE. Damage to the lateral and central, but not other, amygdaloid nuclei prevents the acquisition of auditory fear conditioning. Learn Mem 2001;8:156-63. (Pubitemid 32552864)
232. Nair J, Singh AS. The role of the glutamatergic system in posttraumatic stress disorder. CNS Spectr 2008;13:585-91.
233. Nascimento Hackl LP, Carobrez AP. Distinct ventral and dorsal hippocampus AP5 anxiolytic effects revealed in the elevated plus-maze task in rats. Neurobiol Learn Mem 2007;88:177-85. (Pubitemid 47223755)
234. Niewoehner B, Single FN, Hvalby O, Jensen V, Meyer zum Alten BS, Seeburg PH, et al. Impaired spatial working memory but spared spatial reference memory following functional loss of NMDA receptors in the dentate gyrus. Eur J Neurosci 2007;25:837-46.
235. Nishi M, Hinds H, Lu HP, Kawata M, Hayashi Y. Motoneuron-specific expression of NR3B, a novel NMDA-type glutamate receptor subunit that works in a dominantnegative manner. J Neurosci 2001;21:RC185.
236. Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry 2008;63:1118-26.
237. O'Connor RM, Finger BC, Flor PJ, Cryan JF. Metabotropic glutamate receptor 7: at the interface of cognition and emotion. Eur J Pharmacol 2010;639:123-31.
238. Onishi BK, Xavier GF. Contextual, but not auditory, fear conditioning is disrupted by neurotoxic selective lesion of the basal nucleus of amygdala in rats. Neurobiol Learn Mem 2010;93:165-74.
239. Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, Meunier SA, et al. Efficacy of Dcycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry 2010;67:365-70.
240. Padovan CM, Del Bel EA, Guimaraes FS. Behavioral effects in the elevated plus maze of an NMDA antagonist injected into the dorsal hippocampus: influence of restraint stress. Pharmacol Biochem Behav 2000;67:325-30. (Pubitemid 32000838)
241. Palucha A, Pilc A. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol Ther 2007;115:116-47. (Pubitemid 46992810)
242. Palucha A, Tatarczynska E, Branski P, Szewczyk B, Wieronska JM, Klak K, et al. Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats. Neuropharmacology 2004;46(2):151-9. (Pubitemid 37532823)
243. Pape HC, Pare D. Plastic synaptic networks of the amygdala for the acquisition, expression, and extinction of conditioned fear. Physiol Rev 2010;90:419-63.
244. Pare D, Quirk GJ, Ledoux JE. New vistas on amygdala networks in conditioned fear. J Neurophysiol 2004;92:1-9. (Pubitemid 38802225)
245. Parnas AS, Weber M, Richardson R. Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. Neurobiol Learn Mem 2005;83(3):224-31. (Pubitemid 40488810)
246. Pasquini M, Biondi M. Memantine augmentation for refractory obsessive - compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1173-5. (Pubitemid 43928231)
247. Patat A, Molinier P, Hergueta T, Brohier S, Zieleniuk I, Danjou P, et al. Lack of amnestic, psychotomimetic or impairing effect on psychomotor performance of eliprodil, a new NMDA antagonist. Int Clin Psychopharmacol 1994;9:155-62. (Pubitemid 24317178)
248. Pellegrini-Giampietro DE. An activity-dependent spermine-mediated mechanism that modulates glutamate transmission. Trends Neurosci 2003;26:9-11. (Pubitemid 35463365)
249. Pellow S, File SE. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav 1986;24:525-9. (Pubitemid 16145187)
250. Perez de la MM, Lara-Garcia D, Jacobsen KX, Vazquez-Garcia M, Crespo-Ramirez M, Flores-Gracia C, et al. Anxiolytic-like effects of the selective metabotropic glutamate receptor 5 antagonist MPEP after its intra-amygdaloid microinjection in three different non-conditioned rat models of anxiety. Eur J Neurosci 2006;23(10):2749-59.
251. Pfeiffer CC, Iliev V, Goldstein L, Jenney EH, Schultz R. Blood histamine, polyamines and the schizophrenias. Computer correlations of the low and high blood histamine types. Res Commun Chem Pathol Pharmacol 1970;1:247-65.
252. Pietraszek M, Sukhanov I, Maciejak P, Szyndler J, Gravius A, Wislowska A, et al. Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. Eur J Pharmacol 2005;514:25-34. (Pubitemid 40692760)
253. Pilc A, Klodzinska A, Branski P, Nowak G, Palucha A, Szewczyk B, et al. Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology 2002;43(2):181-7. (Pubitemid 35247606)
254. Piletz JE, May PJ, Wang G, Zhu H. Agmatine crosses the blood - brain barrier. Ann NY Acad Sci 2003;1009:64-74. (Pubitemid 38265091)
255. Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G. Riluzole in the treatment of mood and anxiety disorders. CNS Drugs 2008;22:761-86.
256. Plaznik A, Palejko W, Nazar M, Jessa M. Effects of antagonists at the NMDA receptor complex in two models of anxiety. Eur Neuropsychopharmacol 1994;4:503-12.
257. Poremba A, Gabriel M. Amygdalar efferents initiate auditory thalamic discriminative training-induced neuronal activity. J Neurosci 2001;21:270-8. (Pubitemid 32098750)
258. Porter JH, Wiley JL, Balster RL. Effects of phencyclidine-like drugs on punished behavior in rats. J Pharmacol Exp Ther 1989;248:997-1002. (Pubitemid 19100747)
259. Porter RH, Jaeschke G, Spooren W, Ballard TM, Buttelmann B, Kolczewski S, et al. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther 2005;315:711-21. (Pubitemid 41500737)
260. Poyurovsky M, Weizman R, Weizman A, Koran L. Memantine for treatment-resistant OCD. Am J Psychiatry 2005;162:2191-2.
261. Przegalinski E, Tatarczynska E, ren-Wesolek A, Chojnacka-Wojcik E. Anticonflict effects of a competitive NMDA receptor antagonist and a partial agonist at strychnineinsensitive glycine receptors. Pharmacol Biochem Behav 1996;54:73-7. (Pubitemid 26146664)
262. Quirk GJ, Mueller D. Neural mechanisms of extinction learning and retrieval. Neuropsychopharmacology 2008;33:56-72. (Pubitemid 350191313)
263. Ramchand CN, Das I, Gliddon A, Hirsch SR. Role of polyamines in the membrane pathology of schizophrenia. A study using fibroblasts from schizophrenic patients and normal controls. Schizophr Res 1994;13:249-53. (Pubitemid 24302655)
264. Repa JC, Muller J, Apergis J, Desrochers TM, Zhou Y, Ledoux JE. Two different lateral amygdala cell populations contribute to the initiation and storage of memory. Nat Neurosci 2001;4:724-31. (Pubitemid 32595411)
265. Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004;61:1136-44. (Pubitemid 39463415)
266. Reznikov LR, Grillo CA, Piroli GG, Pasumarthi RK, Reagan LP, Fadel J. Acute stress-mediated increases in extracellular glutamate levels in the rat amygdala: differential effects of antidepressant treatment. Eur J Neurosci 2007;25:3109-14. (Pubitemid 46888811)
267. Rhee HJ, Kim EJ, Lee JK. Physiological polyamines: simple primordial stress molecules. J Cell Mol Med 2007;11:685-703. (Pubitemid 47313311)
268. Riaza Bermudo-Soriano C, Chinchilla Moreno A. Hipótesis glutamatérgica in esquizofrenia. Las esquizofrenias: sus hechos y valores clínicos y terapéuticos. Elsevier, Masson; 2007. p. 240-5.
269. Riaza Bermudo-Soriano C, Puente García R, Chinchilla Moreno A, Rodríguez Quirós J, Vega Piñero M. Neurodesarrollo, esquizotaxia, y modelo diátesis-estrés en esquizofrenia. Las esquizofrenias: sus hechos y valores clínicos y terapéuticos. Masson: Elsevier; 2007. p. 75-99.
270. Riaza Bermudo-Soriano C, Vaquero-Lorenzo C, Diaz-Hernández M, Pérez-Rodríguez MM, Fernández-Piqueras J, Saiz-Ruiz J, et al. SAT-1-1415T/C polymorphism and susceptibility to schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:345-8.
271. Richardson R, Ledgerwood L, Cranney J. Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications. Learn Mem 2004;11:510-6. (Pubitemid 39299697)
272. Richardson-Andrews RC. A central role for the polyamines in the aetiology of schizophrenia. Med Hypotheses 1983;11:157-66.
273. Ritzen A, Mathiesen JM, Thomsen C. Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators. Basic Clin Pharmacol Toxicol 2005;97:202-13. (Pubitemid 41435091)
274. Rock DM, Macdonald RL. Polyamine regulation of N-methyl-D-aspartate receptor channels. Annu Rev Pharmacol Toxicol 1995;35:463-82.
275. Rodrigues SM, Schafe GE, Ledoux JE. Intra-amygdala blockade of the NR2B subunit of the NMDA receptor disrupts the acquisition but not the expression of fear conditioning. J Neurosci 2001;21:6889-96. (Pubitemid 32781131)
276. Rodrigues SM, Farb CR, Bauer EP, Ledoux JE, Schafe GE. Pavlovian fear conditioning regulates Thr286 autophosphorylation of Ca2+/calmodulin-dependent protein kinase II at lateral amygdala synapses. J Neurosci 2004;24:3281-8. (Pubitemid 38451894)
277. Rogan MT, Ledoux JE. LTP is accompanied by commensurate enhancement of auditoryevoked responses in a fear conditioning circuit. Neuron 1995;15:127-36.
278. Rogan MT, Staubli UV, Ledoux JE. Fear conditioning induces associative long-term potentiation in the amygdala. Nature 1997;390:604-7. (Pubitemid 28016193)
279. Rogan MT, Weisskopf MG, Huang Y-Y, Kandel ER, Lee D. Long-term potentiation in the amygdala: implications for memory. Cambridge: Cambridge University Press; 2001.
280. Rorick-Kehn LM, Hart JC, McKinzie DL. Pharmacological characterization of stress-induced hyperthermia in DBA/2 mice using metabotropic and ionotropic glutamate receptor ligands. Psychopharmacology (Berl) 2005;183(2):226-40. (Pubitemid 41609275)
281. Rorick-Kehn LM, Perkins EJ, Knitowski KM, Hart JC, Johnson BG, Schoepp DD, et al. Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344. J Pharmacol Exp Ther 2006;316(2):905-13. (Pubitemid 43131021)
282. Rosenblum K, Dudai Y, Richter-Levin G. Long-term potentiation increases tyrosine phosphorylation of the N-methyl-D-aspartate receptor subunit 2B in rat dentate gyrus in vivo. Proc Natl Acad Sci U S A 1996;93:10457-60.
283. Rosenblum K, Berman DE, Hazvi S, Lamprecht R, Dudai Y. NMDA receptor and the tyrosine phosphorylation of its 2B subunit in taste learning in the rat insular cortex. J Neurosci 1997;17:5129-35. (Pubitemid 27263826)
284. Rostas JA, Brent VA, Voss K, Errington ML, Bliss TV, Gurd JW. Enhanced tyrosine phosphorylation of the 2B subunit of the N-methyl-D-aspartate receptor in longterm potentiation. Proc Natl Acad Sci U S A 1996;93:10452-6.
285. Rubin MA, Boemo RL, Jurach A, Rojas DB, Zanolla GR, Obregon AD, et al. Intrahippocampal spermidine administration improves inhibitory avoidance performance in rats. Behav Pharmacol 2000;11:57-61. (Pubitemid 30223758)
286. Rubin MA, Stiegemeier JA, Volkweis MA, Oliveira DM, Fenili AC, Boemo RL, et al. Intraamygdala spermidine administration improves inhibitory avoidance performance in rats. Eur J Pharmacol 2001;423:35-9. (Pubitemid 32595725)
287. Rubin MA, Berlese DB, Stiegemeier JA, Volkweis MA, Oliveira DM, dos Santos TL, et al. Intra-amygdala administration of polyamines modulates fear conditioning in rats11824. J Neurosci 2004a;24:2328-34. (Pubitemid 38314565)
288. Rubin MA, Berlese DB, Stiegemeier JA, Volkweis MA, Oliveira DM, dos Santos TL, et al. Intra-amygdala administration of polyamines modulates fear conditioning in rats. J Neurosci 2004b;24:2328-34. (Pubitemid 38314565)
289. Sabatini BL, Svoboda K. Analysis of calcium channels in single spines using optical fluctuation analysis. Nature 2000;408:589-93.
290. Sajdyk TJ, Shekhar A. Excitatory amino acid receptor antagonists block the cardiovascular and anxiety responses elicited by gamma-aminobutyric acidA receptor blockade in the basolateral amygdala of rats. J Pharmacol Exp Ther 1997a;283:969-77. (Pubitemid 27514662)
291. Sajdyk TJ, Shekhar A. Excitatory amino acid receptors in the basolateral amygdala regulate anxiety responses in the social interaction test. Brain Res 1997b;764:262-4. (Pubitemid 27380667)
292. Salt TE, Eaton SA. Functions of ionotropic and metabotropic glutamate receptors in sensory transmission in the mammalian thalamus. Prog Neurobiol 1995:55-72.
293. Santini E, Muller RU, Quirk GJ. Consolidation of extinction learning involves transfer from NMDA-independent to NMDA-dependent memory. J Neurosci 2001;21:9009-17. (Pubitemid 33054862)
294. Sapolsky RM. Stress and plasticity in the limbic system. Neurochem Res 2003;28:1735-42. (Pubitemid 37296215)
295. Schafe GE, Ledoux JE. Memory consolidation of auditory pavlovian fear conditioning requires protein synthesis and protein kinase A in the amygdala. J Neurosci 2000;20:RC96.
296. Schafe GE, Nadel NV, Sullivan GM, Harris A, Ledoux JE. Memory consolidation for contextual and auditory fear conditioning is dependent on protein synthesis, PKA, and MAP kinase. Learn Mem 1999;6:97-110. (Pubitemid 29207259)
297. Schafe GE, Atkins CM, Swank MW, Bauer EP, Sweatt JD, Ledoux JE. Activation of ERK/MAP kinase in the amygdala is required for memory consolidation of pavlovian fear conditioning. J Neurosci 2000;20:8177-87.
298. Schoepp DD,Wright RA, Levine LR, Gaydos B, Potter WZ. LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 2003;6(3):189-97. (Pubitemid 37210425)
299. Schulz B, Fendt M, Gasparini F, Lingenhohl K, Kuhn R, Koch M. The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) blocks fear conditioning in rats. Neuropharmacology 2001;41(1):1-7. (Pubitemid 32607639)
300. Schwendt M, Jezova D. Gene expression of two glutamate receptor subunits in response to repeated stress exposure in rat hippocampus. Cell Mol Neurobiol 2000;20:319-29. (Pubitemid 30228224)
301. Seiler N. How important is the oxidative degradation of spermine?: minireview article. Amino Acids 2004;26:317-9. (Pubitemid 39093133)
302. Seiler N, Delcros JG, Moulinoux JP. Polyamine transport in mammalian cells. An update. Int J Biochem Cell Biol 1996;28:843-61. (Pubitemid 26284212)
303. Sequeira A, Gwadry FG, Ffrench-Mullen JM, Canetti L, Gingras Y, Casero Jr RA, et al. Implication of SSAT by gene expression and genetic variation in suicide and major depression. Arch Gen Psychiatry 2006;63:35-48. (Pubitemid 43037467)
304. Sequeira A, Klempan T, Canetti L, Ffrench-Mullen J, Benkelfat C, Rouleau GA, et al. Patterns of gene expression in the limbic system of suicides with and without major depression. Mol Psychiatry 2007;12:640-55. (Pubitemid 46998251)
305. Shekhar A, Keim SR. LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats. Neuropharmacology 2000;39(7):1139-46. (Pubitemid 30173179)
306. Shepard JD, Barron KW, Myers DA. Corticosterone delivery to the amygdala increases corticotropin-releasing factor mRNA in the central amygdaloid nucleus and anxiety-like behavior. Brain Res 2000;861:288-95. (Pubitemid 30173314)
307. Shimazaki T, Iijima M, Chaki S. Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test. Eur J Pharmacol 2004;501(1-3):121-5. (Pubitemid 39298944)
308. Shors TJ, Mathew PR. NMDA receptor antagonism in the lateral/basolateral but not central nucleus of the amygdala prevents the induction of facilitated learning in response to stress. Learn Mem 1998;5:220-30. (Pubitemid 29108881)
309. Shors TJ, Weiss C, Thompson RF. Stress-induced facilitation of classical conditioning. Science 1992;257:537-9.
310. Siegl S, Flor PJ, Fendt M. Amygdaloid metabotropic glutamate receptor subtype 7 is involved in the acquisition of conditioned fear. Neuroreport 2008;19:1147-50.
311. Silvestre JS, Nadal R, Pallares M, Ferre N. Acute effects of ketamine in the holeboard, the elevated-plus maze, and the social interaction test in Wistar rats. Depress Anxiety 1997;5:29-33. (Pubitemid 28106010)
312. Smialowska M, Wieronska JM, Domin H, Zieba B. The effect of intrahippocampal injection of group II and III metobotropic glutamate receptor agonists on anxiety; the role of neuropeptide Y. Neuropsychopharmacology 2007;32(6):1242-50. (Pubitemid 46788861)
313. Soderpalm AK, Blomqvist O, Engel JA, Soderpalm B. Characterization of the anticonflict effect of MK-801, a non-competitive NMDA antagonist. Pharmacol Toxicol 1995;76:122-7.
314. Spooren WP, Vassout A, Neijt HC, Kuhn R, Gasparini F, Roux S, et al. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther 2000;295(3):1267-75.
315. Spooren WP, Schoeffter P, Gasparini F, Kuhn R, Gentsch C. Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608). Eur J Pharmacol 2002;435(2-3):161-70. (Pubitemid 34131696)
316. Sprosen TS, Woodruff GN. Polyamines potentiate NMDA induced whole-cell currents in cultured striatal neurons. Eur J Pharmacol 1990;179:477-8. (Pubitemid 20137521)
317. Stachowicz K, Klak K, Klodzinska A, Chojnacka-Wojcik E, Pilc A. Anxiolytic-like effects of PHCCC, an allosteric modulator of mGlu4 receptors, in rats. Eur J Pharmacol 2004;498:153-6. (Pubitemid 39208074)
318. Stachowicz K, Klak K, Pilc A, Chojnacka-Wojcik E. Lack of the antianxiety-like effect of (S)-3,4-DCPG, an mGlu8 receptor agonist, after central administration in rats. Pharmacol Rep 2005;57(6):856-60.
319. Stachowicz K, Chojnacka-Wojcik E, Klak K, Pilc A. Anxiolytic-like effects of group III mGlu receptor ligands in the hippocampus involve GABAA signaling. Pharmacol Rep 2006;58:820-6. (Pubitemid 46117733)
320. Stachowicz K, Chojnacka-Wojcik E, Klak K, Pilc A. Anxiolytic-like effect of group III mGlu receptor antagonist is serotonin-dependent. Neuropharmacology 2007;52:306-12. (Pubitemid 46123350)
321. Stachowicz K, Branski P, Klak K, van der PH, Cryan JF, Flor PJ, et al. Selective activation of metabotropic G-protein-coupled glutamate 7 receptor elicits anxiolytic-like effects in mice by modulating GABAergic neurotransmission. Behav Pharmacol 2008;19:597-603.
322. Stachowicz K, Klodzinska A, Palucha-Poniewiera A, Schann S, Neuville P, Pilc A. The group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not antidepressant- like effects, mediated by the serotonergic and GABA-ergic systems. Neuropharmacology 2009;57:227-34.
323. Stahl SM. Stahl's essential psychopharmacologyneuroscientific basis and practical applications. Cambridge: Cambridge University Press; 2008.
324. Steckler T, Lavreysen H, Oliveira AM, Aerts N, Van CH, Prickaerts J, et al. Effects of mGlu1 receptor blockade on anxiety-related behaviour in the rat lick suppression test. Psychopharmacology (Berl) 2005;179:198-206. (Pubitemid 40576707)
325. Stewart SE, Jenike EA, Hezel DM, Stack DE, Dodman NH, Shuster L, et al. A single-blinded case-control study of memantine in severe obsessive - compulsive disorder. J Clin Psychopharmacol 2010;30:34-9.
326. Stromgaard K, Mellor I. AMPA receptor ligands: synthetic and pharmacological studies of polyamines and polyamine toxins. Med Res Rev 2004;24:589-620. (Pubitemid 39043675)
327. Stuart GJ, Hausser M. Dendritic coincidence detection of EPSPs and action potentials. Nat Neurosci 2001;4:63-71. (Pubitemid 32095527)
328. Svinarev VI. Polyamine studies of schizophrenia patients. Vrach Delo 1986:88-9.
329. Szapiro G, Barros DM, Ardenghi P, Vianna MR, Choi H, Silva T, et al. Facilitation and inhibition of retrieval in two aversive tasks in rats by intrahippocampal infusion of agonists of specific glutamate metabotropic receptor subtypes. Psychopharmacology (Berl) 2001;156(4):397-401. (Pubitemid 32695848)
330. Tadano T, Hozumi S, Yamadera F, Murata A, Niijima F, Tan-No K, et al. Effects of NMDA receptor-related agonists on learning and memory impairment in olfactory bulbectomized mice. Methods Find Exp Clin Pharmacol 2004;26:93-7. (Pubitemid 38453709)
331. Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M, et al. Genetic enhancement of learning and memory in mice. Nature 1999;401:63-9.
332. Tatarczynska E, Klodzinska A, Kroczka B, Chojnacka-Wojcik E, Pilc A. The antianxietylike effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration. Psychopharmacology (Berl) 2001;158:94-9.
333. Tatarczynska E, Palucha A, Szewczyk B, Chojnacka-Wojcik E, Wieronska J, Pilc A. Anxiolytic- and antidepressant-like effects of group III metabotropic glutamate agonist (1S,3R,4S)-1-aminocyclopentane-1,3,4-tricarboxylic acid (ACPT-I) in rats. Pol J Pharmacol 2002;54:707-10. (Pubitemid 36124524)
334. Thomas T, Thomas TJ. Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci 2001;58:244-58. (Pubitemid 32217356)
335. Tizzano JP, Griffey KI, Schoepp DD. The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam. Pharmacol Biochem Behav 2002;73(2):367-74. (Pubitemid 34773438)
336. Tonetto LL, Terzian AL, Del Bel EA, Guimaraes FS, Resstel LB. Inhibition of the NMDA receptor/Nitric Oxide pathway in the dorsolateral periaqueductal gray causes anxiolytic-like effects in rats submitted to the Vogel conflict test. Behav Brain Funct 2009;5:40.
337. Traynelis SF, Hartley M, Heinemann SF. Control of proton sensitivity of the NMDA receptor by RNA splicing and polyamines. Science 1995;268:873-6.
338. Tsien JZ. Linking Hebb's coincidence-detection to memory formation. Curr Opin Neurobiol 2000;10:266-73. (Pubitemid 30201122)
339. Turecki, G. Using brain expression studies to gain insight into the neurobiology of major depression and suicide. McGill Group for Suicide Studies Douglas Hospital Research Center McGill University. http://www. microarraybulletin.com/community/symposium/speaker/slides/turecki/ Turecki-AMB-Symposium-3-16-06-files/frame.htm#slide0146.htm2006 Ref Type: Electronic Citation.
340. Ugolini A, Large CH, Corsi M. AMN082, an allosteric mGluR7 agonist that inhibits afferent glutamatergic transmission in rat basolateral amygdala. Neuropharmacology 2008;55:532-6.
341. Uhde T, Galloway M, Fang J. Sleep deprivation and excitatory amino acids. Neuropsychopharmacology 2004;29:s213.
342. Van AM, Mancini C, Pipe B, Oakman J, Bennett M. An open trial of topiramate in the treatment of generalized social phobia. J Clin Psychiatry 2004;65:1674-8.
343. Vaquero-Lorenzo C, Riaza Bermudo-Soriano C, Pérez-Rodríguez MM, Díaz-Hernández M, López-Castromán J, Fernández-Piqueras J, et al. Positive association between SAT-1-1415T/C polymorphism and anxiety. Am J Med Genet B Neuropsychiatr Genet 2008:1-4.
344. Varty GB, Grilli M, Forlani A, Fredduzzi S, Grzelak ME, Guthrie DH, et al. The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles. Psychopharmacology (Berl) 2005;179:207-17. (Pubitemid 40576708)
345. Von EJ, Doganci B, Jensen V, Hvalby O, Gongrich C, Taylor A, et al. Contribution of hippocampal and extra-hippocampal NR2B-containing NMDA receptors to performance on spatial learning tasks. Neuron 2008;60:846-60.
346. Vujcic S, Diegelman P, Bacchi CJ, Kramer DL, Porter CW. Identification and characterization of a novel flavin-containing spermine oxidase of mammalian cell origin. Biochem J 2002;367:665-75. (Pubitemid 35305705)
347. Vyas A, Mitra R, Shankaranarayana Rao BS, Chattarji S. Chronic stress induces contrasting patterns of dendritic remodeling in hippocampal and amygdaloid neurons. J Neurosci 2002;22:6810-8. (Pubitemid 35386438)
348. Vyas A, Bernal S, Chattarji S. Effects of chronic stress on dendritic arborization in the central and extended amygdala. Brain Res 2003;965:290-4. (Pubitemid 36183715)
349. Walker DL, Davis M. Involvement of NMDA receptors within the amygdala in shortversus long-term memory for fear conditioning as assessed with fear-potentiated startle. Behav Neurosci 2000;114(6):1019-33. (Pubitemid 32001882)
350. Walker DL, Davis M. The role of amygdala glutamate receptors in fear learning, fear-potentiated startle, and extinction. Pharmacol Biochem Behav 2002;71:379-92. (Pubitemid 34117707)
351. Walker DL, Rattiner LM, Davis M. Group II metabotropic glutamate receptors within the amygdala regulate fear as assessed with potentiated startle in rats. Behav Neurosci 2002;116(6):1075-83. (Pubitemid 35429642)
352. Wallace KJ, Rosen JB. Neurotoxic lesions of the lateral nucleus of the amygdala decrease conditioned fear but not unconditioned fear of a predator odor: comparison with electrolytic lesions. J Neurosci 2001;21:3619-27. (Pubitemid 32422826)
353. Wang Y, Casero Jr RA. Mammalian polyamine catabolism: a therapeutic target, a pathological problem, or both? J Biochem 2006;139:17-25. (Pubitemid 43258842)
354. Wang Y, Devereux W, Woster PM, Casero Jr RA. Cloning and characterization of the mouse polyamine-modulated factor-1 (mPMF-1) gene: an alternatively spliced homologue of the human transcription factor. Biochem J 2001;359:387-92. (Pubitemid 32999784)
355. Weisskopf MG, Ledoux JE. Distinct populations of NMDA receptors at subcortical and cortical inputs to principal cells of the lateral amygdala. J Neurophysiol 1999;81:930-4. (Pubitemid 29264536)
356. Wieronska JM, Pilc A. Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs. Neurochem Int 2009;55:85-97.
357. Wieronska JM, Szewczyk B, Palucha A, Branski P, Smialowska M. Involvement of CRF but not NPY in the anxiety regulation via NMDA receptors. Pol J Pharmacol 2003;55:1119-24. (Pubitemid 38128950)
358. Wieronska JM, Smialowska M, Branski P, Gasparini F, Klodzinska A, Szewczyk B, et al. In the amygdala anxiolytic action of mGlu5 receptors antagonist MPEP involves neuropeptide Y but not GABAA signaling. Neuropsychopharmacology 2004;29(3):514-21. (Pubitemid 38365927)
359. Wieronska JM, Szewczyk B, Palucha A, Branski P, Zieba B, Smialowska M. Anxiolytic action of group II and III metabotropic glutamate receptors agonists involves neuropeptide Y in the amygdala. Pharmacol Rep 2005;57(6):734-43.
360. Wieronska JM, Klak K, Palucha A, Branski P, Pilc A. Citalopram influences mGlu7, but not mGlu4 receptors' expression in the rat brain hippocampus and cortex. Brain Res 2007;1184:88-95. (Pubitemid 350160601)
361. Wilensky AE, Schafe GE, Kristensen MP, Ledoux JE. Rethinking the fear circuit: the central nucleus of the amygdala is required for the acquisition, consolidation, and expression of Pavlovian fear conditioning. J Neurosci 2006;26:12387-96. (Pubitemid 44864503)
362. Wiley JL. Behavioral pharmacology of N-methyl-D-aspartate antagonists: implications for the study and pharmacotherapy of anxiety and schizophrenia. Exp Clin Psychopharmacol 1997;5:365-74. (Pubitemid 27490383)
363. Wiley JL, Cristello AF, Balster RL. Effects of site-selective NMDA receptor antagonists in an elevated plus-maze model of anxiety in mice. Eur J Pharmacol 1995;294:101-7. (Pubitemid 26016818)
364. Willetts J, Clissold DB, Hartman TL, Brandsgaard RR, Hamilton GS, Ferkany JW. Behavioral pharmacology of NPC 17742, a competitive N-methyl-D-aspartate (NMDA) antagonist. J Pharmacol Exp Ther 1993;265:1055-62. (Pubitemid 23321001)
365. Williams K. Interactions of polyamines with ion channels. Biochem J 1997a;325(Pt 2):289-97. (Pubitemid 27338704)
366. Williams K. Modulation and block of ion channels: a new biology of polyamines. Cell Signal 1997b;9:1-13. (Pubitemid 27120861)
367. Williams K, Dawson VL, Romano C, Dichter MA, Molinoff PB. Characterization of polyamines having agonist, antagonist, and inverse agonist effects at the polyamine recognition site of the NMDA receptor. Neuron 1990;5:199-208. (Pubitemid 20262698)
368. Williams K, Romano C, Dichter MA, Molinoff PB. Modulation of the NMDA receptor by polyamines. Life Sci 1991;48:469-98.
369. Williams K, Zappia AM, Pritchett DB, Shen YM, Molinoff PB. Sensitivity of the N-methyl-D-aspartate receptor to polyamines is controlled by NR2 subunits. Mol Pharmacol 1994;45:803-9. (Pubitemid 24155769)
370. Xie ZC, Buckner E, Commissaris RL. Anticonflict effect of MK-801 in rats: time course and chronic treatment studies. Pharmacol Biochem Behav 1995;51:635-40.
371. Yoshimizu T, Shimazaki T, Ito A, Chaki S. An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology (Berl) 2006;186(4):587-93. (Pubitemid 43855846)
372. Zdanys K, Tampi RR. A systematic review of off-label uses of memantine for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1362-74. (Pubitemid 352033662)
373. Zhao MG, Toyoda H, Lee YS, Wu LJ, Ko SW, Zhang XH, et al. Roles of NMDA NR2B subtype receptor in prefrontal long-term potentiation and contextual fear memory. Neuron 2005;47:859-72. (Pubitemid 41266952)
374. Ziegler DR, Cullinan WE, Herman JP. Organization and regulation of paraventricular nucleus glutamate signaling systems: N-methyl-D-aspartate receptors. J Comp Neurol 2005;484:43-56. (Pubitemid 40315404)
375. Zomkowski AD, Hammes L, Lin J, Calixto JB, Santos AR, Rodrigues AL. Agmatine produces antidepressant-like effects in two models of depression in mice. Neuroreport 2002;13:387-91. (Pubitemid 34293175)